Using a deep convolutional neural network can improve providers’ ability to predict how patients with hepatocellular carcinoma will respond to Y90-RE treatment, enabling them to offer additional therapies, if necessary.
Providers can do a better job of predicting how patients with hepatocellular cancer (HCC) will respond to Yttrium-90 radioembolization (Y90-RE) treatment when they use a deep convolutional neural network (DNN).
In a poster presented during the Society for Imaging Informatics in Medicine (SIIM) 2021 Virtual Annual Meeting, William Wagstaff, M.D., MS, a third-year radiology and imaging sciences resident at Emory University School of Medicine, revealed that applying the algorithm improved the ability to determine how a patient will respond to Y90-RE therapy.
“The deep learning algorithm had a 16-percent higher area under the receiver operating characteristic curve (ROC-AUC) for predicting immediate, post-radioembolization treatment response in patients with HCC compared to the current best method,” he explained. “This algorithm has the potential to highlight patients that may benefit from earlier follow-up or additional therapy.
For more coverage of SIIM 2021, click here.
Only a small number of patients with HCC qualify for curative surgery or transplant, so Y90-RE is the alternative treatment method. However, a patient’s response to Y90-RE is assessed via imaging after three-to-six months, potentially giving the tumor time to progress or metastasize. To find out whether using a DNN could help providers predict a patient’s Y90-RE response, Wagstaff’s team conducted a retrospective analysis on HCC patients who received Y90-RE treatment between December 2014 and January 2019 at a single institution.
For their study, they divided 77 patients with a total of 103 lesions who had no prior Y90-RE therapy into two groups – 57 with complete response to treatment and 46 with incomplete response. They hand-segmented lesions on pre-treatment arterial phase MRI to pinpoint lesion location, as well as on post-treatment arterial phase MRI to determine slice-wise response, and they used immediate post-Y90-RE SPECT as a proxy for treatment area and dose. Ninety percent of lesions were in a training set, and 10 percent were part of a hold-out test set.
Based on their analysis, the five-fold cross-validation results for the ensemble model were sensitivity of 0.73 +/- 0.29, specificity of 0.70 +/- 0.14, accuracy of 0.75 +/- 0.09, and ROC-AUC of 0.79 +/- 0.12. By comparison, the partition model had a sensitivity of 0.36 +/- 0.34, specificity of 0.80 +/- 0.40, accuracy of 0.63 +/- 0.04, and ROC-AUC of 0.62 +/- 0.09.
In addition, test set results for the ensemble model were sensitivity 0.32, specificity 0.85, accuracy 0.65, and ROC-AUC 0.66, and the results for the partition model were sensitivity 0.03, specificity 0.99, accuracy 0.62, and ROC-AUC 0.57.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.